Trial reportDermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.]2016
Bimatoprost 0.03% for the Treatment of Eyebrow Hypotrichosis.
Trial report in Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.], 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01765764 (Bimatoprost for the Treatment of Eyebrow Hypotrichosis), which is not on this map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Bimatoprost for the Treatment of Eyebrow Hypotrichosis
Who cites it
11 citing papers in PubMed.
- Topical latanoprost acid for female androgenetic alopecia: a pilot proof-of-concept trial with mechanistic evidence of prostaglandin F2α receptor activation.Pharmacological reports : PR · 2026Trial
- Comparative study of the efficacy and safety of topical minoxidil 2% versus topical bimatoprost 0.01% versus topical bimatoprost 0.03% in treatment of eyebrow hypotrichosis: a randomized controlled trial.Archives of dermatological research · 2023Trial
- Prostaglandin FFrontiers in physiology · 2025Article
- From Eye Care to Hair Growth: Bimatoprost.Pharmaceuticals (Basel, Switzerland) · 2024Review
- Eyebrow and Eyelash Alopecia: A Clinical Review.American journal of clinical dermatology · 2023Review
- The efficacy of topical prostaglandin analogs for hair loss: A systematic review and meta-analysis.Frontiers in medicine · 2023Review
- Preparation of topical bimatoprost with enhanced skin infiltration andDrug delivery · 2022Article
- Advances in hair growth.Faculty reviews · 2022Review
- Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata.American journal of clinical dermatology · 2020Article
- Topical Treatment of Eyebrow Hypotrichosis with Bimatoprost 0.03% Solution: Case Report and Literature Review.Cureus · 2018Article
- Therapeutic potential of bimatoprost for the treatment of eyebrow hypotrichosis.Drug design, development and therapy · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundEyebrow loss may have substantial negative functional and social consequences.
objectiveEvaluate the safety and efficacy of bimatoprost 0.03% in subjects with eyebrow hypotrichosis.
methodsThis multicenter, double-masked study randomized adult females or males with eyebrow hypotrichosis to receive bimatoprost 0.03% twice (BID) or once daily (QD) or vehicle BID for 7 months. Primary endpoint was overall eyebrow fullness at Month 7. Secondary endpoints included eyebrow fullness (mm), darkness (intensity units), and subject satisfaction with treatment. Safety was also assessed.
resultsAt Month 7, the proportion of subjects with improvement was significantly higher in bimatoprost groups versus vehicle (both, p < .001). Improvements occurred in both bimatoprost groups versus vehicle after Month 1 and continued through follow-up; eyebrow fullness and darkness improved as early as Months 2 and 1, respectively (both, p < .001). Greater satisfaction was reported with bimatoprost versus vehicle at Month 2 and all subsequent time points. Overall, 38.1%, 42.4%, and 35.5% of subjects in the bimatoprost BID, QD, and vehicle groups, respectively, experienced ≥1 treatment-emergent adverse event (TEAE). Most frequent TEAEs were similar across groups. No skin or iris hyperpigmentation or conjunctival hyperemia occurred.
conclusionBimatoprost 0.03% BID and QD is safe, well tolerated, and effective for eyebrow hypotrichosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.